AT-101 (R-(-)-gossypol acetic acid) enhances the effectiveness of androgen deprivation therapy in the VCaP prostate cancer model

Journal of Cellular Biochemistry

Volumn 110, Issue 5, 2010, Pages 1187-1194

  McGregor, Natalie ^a   Patel, Lalit ^a   Craig, Matthew ^a   Weidner, Savannah ^a   Wang, Shaomeng ^a,b   Pienta, Kenneth J ^a,b,c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Androgen deprivation therapy; Apoptosis; BCL 2; Gossypol; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; BICALUTAMIDE; CASPASE; GOSSYPOL ACETIC ACID; ISOSORBIDE; PROTEIN BCL 2;

ANDROGEN DEPRIVATION THERAPY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER MODEL; CANCER PATIENT; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; DOWN REGULATION; ENZYME ACTIVATION; HUMAN; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEIN EXPRESSION; TUMOR XENOGRAFT;

ANDROGEN ANTAGONISTS; ANDROGENS; ANILIDES; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BCL-X PROTEIN; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DIHYDROTESTOSTERONE; DRUG SYNERGISM; GOSSYPOL; HUMANS; IMMUNOBLOTTING; MALE; NITRILES; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, ANDROGEN; TOSYL COMPOUNDS;

EID: 77954934989     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.22633     Document Type: Article

References (32)

1. Chipuk JE, Green DR. 2008. How do BCL-2 proteins induce mitochondrial outer membrane permeabilization? Trends Cell Biol 18:157-164.
2. Cory S, Adams JM. 2002. The Bcl2 family: Regulators of the cellular life-or-death switch. Nat Rev Cancer 2:647-656. (Pubitemid 37328916)
3. Eder IE, Culig Z, Putz T, Nessler-Menardi C, Bartsch G, Klocker H. 2001. Molecular biology of the androgen receptor: From molecular understanding to the clinic. Eur Urol 40:241-251. (Pubitemid 34701893)
4. Frenzel A, Grespi F, Chmelewskij W, Villunger A. 2009. Bcl2 family proteins in carcinogenesis and the treatment of cancer. Apoptosis 14:584-596.
5. Fujimoto N, Chang C, Nomura M, Matsumoto T. 2005. Can we prevent prostate cancer? Rationale and current status of prostate cancer chemoprevention. Urol Int 74:289-297. (Pubitemid 40864150)
6. Heinlein CA, Chang C. 2004. Androgen receptor in prostate cancer. Endocr Rev 25:276-308.
7. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. 1990. Bcl- 2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348:334-336. (Pubitemid 120029101)
8. Huang X, Zhang X, Farahvash B, Olumi AF. 2007. Novel targeted proapoptotic agents for the treatment of prostate cancer. J Urol 178:1846-1854. (Pubitemid 47538573)
9. Huggins C, Hodges CV. 1941. Studies on prostatic cancer II: the effects of castration on advanced carcinoma of the prostate gland.Arch Surg 43:209-223.
10. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. 2009. Cancer statistics, 2009. CA Cancer J Clin 59:225-249.
11. Kline MP, Rajkumar SV, Timm MM, Kimlinger TK, Haug JL, Lust JA, Greipp PR, Kumar S. 2008. R-(-)-gossypol (AT-101) activates programmed cell death in multiple myeloma cells. Exp Hematol 36:568-576.
12. Korenchuk S, Lehr JE, MClean L, Lee YG, Whitney S, Vessella R, Lin DL, Pienta KJ. 2001. VCaP, a cell-based model system of human prostate cancer. In Vivo 15:163-168. (Pubitemid 32328191)
13. Liu G, Kelly WK, Wilding G, Leopold L, Brill K, Somer B. 2009. An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer. Clin Cancer Res 15:3172-3176.
14. Loberg RD, St John LN, Day LL, Neeley CK, Pienta KJ. 2006. Development of the VCaP androgen-independent model of prostate cancer. Urol Oncol 24:161-168.
15. Loberg RD, McGregor N, Ying C, Sargent E, Pienta KJ. 2007. In vivo evaluation of AT-101 (R-(-)-gossypol acetic acid) in androgen-independent growth of VCaP prostate cancer cells in combination with surgical castration. Neoplasia 9:1030-1037.
16. Ma WW, Adjei AA. 2009. Novel agents on the horizon for cancer therapy. CA Cancer J Clin 59:111-137.
17. Macoska JA, Adsule S, Tantivejkul K, Wang S, Pienta KJ, Lee CT. 2008. - (-)Gossypol promotes the apoptosis of bladder cancer cells in vitro. Pharmacol Res 58:323-331.
18. Marzo I, Naval J. 2008. Bcl-2 family members as molecular targets in cancer therapy. Biochem Pharmacol 76:939-946.
19. Meng Y, Tang W, Dai Y, Wu X, Liu M, Ji Q, Ji M, Pienta K, Lawrence T, Xu L. 2008. Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa. Mol Cancer Ther 7:2192-2202.
20. Miyamoto H, Messing EM, Chang C. 2004. Androgen deprivation therapy for prostate cancer: Current status and future prospects. Prostate 61:332-353. (Pubitemid 39571710)
21. Pegoraro L, Palumbo A, Erikson J, Falda M, Giovanazzo B, Emanuel BS, Rovera G, Nowell PC, Croce CM. 1984. A 14;18 and an 8;14 chromosome translocation in a cell line derived from an acute B-cell leukemia. Proc Natl Acad Sci USA 81:7166-7170.
22. Perlmutter MA, Lepor H. 2007. Androgen deprivation therapy in the treatment of advanced prostate cancer. Rev Urol 9(Suppl 1): S3-S8.
23. Petros AM, Olejniczak ET, Fesik SW. 2004. Structural biology of the Bcl-2 family of proteins. Biochim Biophys Acta 1644:83-94.
24. Pienta KJ, Bradley D. 2006. Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res 12:1665-1671.
25. Sun A, Tang J, Hong Y, Song J, Terranova PF, Thrasher JB, Svojanovsky S, Wang HG, Li B. 2008. Androgen receptor-dependent regulation of Bcl-xL expression: Implication in prostate cancer progression. Prostate 68:453-461. (Pubitemid 351342650)
26. Taichman RS, Loberg RD, Mehra R, Pienta KJ. 2007. The evolving biology and treatment of prostate cancer. J Clin Invest 117:2351-2361. (Pubitemid 47494332)
27. Tsujimoto Y, Finger LR, Yunis J, Nowell PC, Croce CM. 1984. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science 226:1097-1099. (Pubitemid 15217831)
28. van Bokhoven A, Varella-Garcia M, Korch C, Johannes WU, Smith EE, Miller HL, Nordeen SK, Miller GJ, Lucia MS. 2003. Molecular characterization of human prostate carcinoma cell lines. Prostate 57:205-225. (Pubitemid 37267805)
29. Walczak JR, Carducci MA. 2007. Prostate cancer: A practical approach to current management of recurrent disease. Mayo Clin Proc 82:243-249. (Pubitemid 46198485)
30. Wang G, Nikolovska-Coleska Z, Yang CY, Wang R, Tang G, Guo J, Shangary S, Qiu S, Gao W, Yang D, Meagher J, Stuckey J, Krajewski K, Jiang S, Roller PP, Abaan HO, Tomita Y, Wang S. 2006. Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. J Med Chem 49:6139-6142. (Pubitemid 44595187)
31. Youle RJ, Strasser A. 2008. The BCL-2 protein family: Opposing activities that mediate cell death. Nat Rev Mol Cell Biol 9:47-59.
32. Zhang M, Liu H, Tian Z, Griffith BN, Ji M, Li QQ. 2007. Gossypol induces apoptosis in human PC-3 prostate cancer cells by modulating caspase-dependent and caspase-independent cell death pathways. Life Sci 80:767-774. (Pubitemid 46108000)